Walder Wyss advises CRISPR on USD 310 Million Share Offering
3 December 2019 – In November/December 2019, CRISPR Therapeutics AG, Switzerland (Nasdaq: CRSP) (CRISPR) carried out an underwritten offering of 4,887,500 shares (including overallotment shares), resulting in gross proceeds of approximately USD 310 million. Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Jefferies LLC acted as joint book-running managers for the offering. Chardan Capital Markets LLC, Oppenheimer & Co. Inc., BTIG, LLC and Roth Capital Partners, LLC were acting as co-managers for the offering.
CRISPR is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR is headquartered in Zug, Switzerland. CRISPR’s common shares are listed on the Nasdaq.
Walder Wyss has acted as Swiss counsel to CRISPR in connection with the transaction. The team is being led by Alex Nikitine (Partner, Corporate/M&A, Capital Markets) and further includes Rafael Zemp (Managing Associate, Corporate/M&A, Capital Markets), Christian Lütolf (Associate, Corporate/M&A), Maurus Winzap (Partner, Tax) and Janine Corti (Counsel, Tax).